EDUCATION EDUCATION

IMF NURSE LEADERSHIP BOARD’S IMPACT IN 2022

The IMF Nurse Leadership Board® (NLB) consists of nurse experts from leading medical centers who care for myeloma patients and who collaborate to improve their patients’ lives. The following outlines their key activities in Fiscal Year 2022.

This fiscal year, NLB members served as faculty at IMF education forums, including 4 Patient and Family Webinars, 10 IMF Regional Community Workshops, and 10 virtual support group presentations that reached over 14,000 participants. They also took part in M-Power Community Workshops to tackle awareness of multiple myeloma risks and disparities among African American communities in Atlanta, Charlotte, and New York.

On April 28, 2022, NLB members Beth Faiman, PhD, MSN, APN-BC, AOCN® BMTCN® FAAN, FAPO; Kimberly Noonan, DNP, ANP-BC, AOCN®; and Donna D. Catamero, ANP-BC, OCN, CCRC presented the “New Drugs, Regimens, and Strategies for Multiple Myeloma: Case Studies for Nurses” symposium at the 47th Annual Oncology Nursing Society (ONS) Congress in Anaheim, California.

Additionally, the NLB participated in the Support Group Leaders Summit and Support Group Leaders at ASH. They also conducted numerous roundtables with both patients and professionals to fulfill their mission of improving care and quality of life for myeloma patients.

Also, at the NLB’s 18th annual meeting in September, members discussed addressing unmet needs of patients in the myeloma community and made plans for 2023, including a focus on addressing disparities in clinical trials, developing educational materials for both patients and nurses on the most up-to-date treatments, developing the new 2023 patient education slide deck, expanding the video library of “Myeloma University” educational modules, updating myeloma case studies, and more.

Finally, in the fall of 2022, the NLB created a myeloma supplement for nurses published in JADPRO—a professional journal geared towards advanced practitioners (APs) in oncology. The supplement features a series of Grand Round articles that use a case-based approach to focus on myeloma topics: Newly Diagnosed Multiple Myeloma Relapsed Multiple Myeloma

• Special Populations in Relapsed Multiple Myeloma

• CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma

• Waldenström Macroglobulinemia and AL Amyloidosis

The JADPRO Supplement entitled Continuing Education Information: Multiple Myeloma and Plasma Cell Disorders: Update on Diagnosis, Prognosis, Treatment, and Supportive Care can be accessed from https:// mmsm.link/JADPRO-July-22

IMF’S M-POWER PROJECT RAISES AWARENESS OF MYELOMA AND EMPOWERS AFRICAN AMERICAN COMMUNITIES

The first ever M-Power Project—a multiyear, multidisciplinary initiative designed to empower people to change the course of myeloma by removing barriers to early diagnosis and treatment in the African American community—was launched in March 2021.

To that end, the IMF worked with Atrium Health Levine Cancer Institute’s Disparities & Outreach program in Charlotte, NC, and enlisted local leaders and healthcare professionals in promoting increased knowledge about this treatable but little-known disease. Since then, the IMF has launched M-Power initiatives across the U.S. and has held FREE community workshops covering topics about multiple myeloma that are relevant to the African American community. Topics include symptoms, diagnosis, treatments, getting the best care, and patient perspectives.

To date, the IMF M-Power Project has been launched in these major U.S. cities:

• M-Power Charlotte Launch—March 2021

• M-Power Baltimore Launch – September 2021

• M-Power Atlanta Launch – November 2021

• 2nd M-Power Charlotte Workshop – June 2022

• M-Power New York – October 2022

Visit the IMF M-Power website at mpower.myeloma.org to view videos on abstracts on racial disparities in myeloma care, clinical trials, and health equity among African Americans. Also housed on the site is a Myeloma Tool Kit with helpful information on drug reimbursement and assistance, finding a Support Group, refresher courses on multiple myeloma, and a glossary of myeloma terms.

“Mortality rates from multiple myeloma are TWICE as high in African Americans than all other races. Also, people of African descent often experience delayed diagnosis and reduced access to critical therapies. These findings are our organization’s call to action to raise awareness and reduce disparities.”

DR. JOSEPH MIKHAEL IMF Chief Medical Officer

TELECONFERENCES

ADDED 25 NEW EDITIONS IN THE IMF’S LIBRARY OF 100+ PUBLICATIONS

IMF’S POPULAR BROADCAST “LIVING WELL WITH MYELOMA” HAS 2,000 LISTENERS

A ND 16,000 ARCHIVED LISTENERS

THROUGHOUT THE COVID-19 PANDEMIC, THE INFOLINE TEAM HAS RESPONDED TO MORE THAN 6,000 CALLS AND EMAILS TO ADDRESS SPECIFIC NEEDS OF MYELOMA PATIENTS ACROSS THE GLOBE

HOSTED

SEMINARS

2,000

10,000+

17 PATIENT & FAMILY SEMINARS

HYBRID CONDUCTED IN PERSON AND VIRTUALLY

REACH INCREASE

15 ,148 19% REACH INCREASE

114 6,500+

12 7,5 90 EMPOWERED PATIENTS & CARE PARTNERS THROUGH 942 SUPPORT GROUP VISITS, EDUCATIONAL MEETINGS AND TECH SUPPORT ENGAGED 12 SUPPORT GROUP LEADERS

TO ASH IN PERSON AND VIRTUALLY TO

SHARE THE PATIENT PERSPECTIVE ON SOCIAL MEDIA & BLOGS REACHING 1,000s